Hypoxia-dependent anti-inflammatory pathways in protection of cancerous tissues

Cancer and Metastasis Reviews

Volumn 26, Issue 2, 2007, Pages 273-279

  Lukashev, D ^a   Ohta, A ^a   Sitkovsky, M ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Adenosine; Cancer; Hypoxia; Immunotherapy; T cells

Indexed keywords

ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE DEAMINASE; ADENOSINE KINASE; ADENOSINE PHOSPHATE; ADENOSYLHOMOCYSTEINASE; CD39 ANTIGEN; CD8 ANTIGEN; CYCLIC AMP; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; G PROTEIN COUPLED RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INOSINE; T LYMPHOCYTE ANTIGEN; T LYMPHOCYTE RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; CANCER; CANCER IMMUNOTHERAPY; CANCER TISSUE; CD8+ T LYMPHOCYTE; ENZYME ACTIVITY; EXTRACELLULAR FLUID; HUMAN; HYPOXIA; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MICROENVIRONMENT; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PROTECTION; PROTEIN METABOLISM; REVIEW; TISSUE INJURY; TISSUE PRESERVATION;

ADENOSINE; CELL HYPOXIA; HUMANS; INFLAMMATION; NEOPLASMS; RECEPTORS, PURINERGIC P1; T-LYMPHOCYTES;

EID: 34547120458     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-007-9054-2     Document Type: Review

References (92)

1. Rosenberg, H. F., & Gallin, J. I. (1999). Inflammation. In W. E. Paul (Ed.), Fundamental immunology (pp. 1051-1062). Philadelphia: Lippincott-Raven.
2. Holloway, A. F., Rao, S., & Shannon, M. F. (2002). Regulation of cytokine gene transcription in the immune system. Molecular Immunology, 38, 567-80.
3. Sitkovsky, M. V., & Ohta, A. (2005). The 'danger' sensors that STOP the immune response: The A2 adenosine receptors? Trends in Immunology, 26, 299-304.
4. Ohta, A., & Sitkovsky, M. (2001). Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature, 414, 916-920.
5. Lukashev, D., Ohta, A., Apasov, S., Chen, J. F., & Sitkovsky, M. (2004). Cutting edge: Physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo. Journal of Immunology, 173, 21-24.
6. Linden, J. (2001). Molecular approach to adenosine receptors: Receptor-mediated mechanisms of tissue protection. Annual Review of Pharmacology and Toxicology, 41, 775-787.
7. Sitkovsky, M. V., Lukashev, D., Apasov, S., Kojima, H., Koshiba, M., Caldwell, C., et al. (2004). Thiel M: Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annual Review of Immunology, 22, 657-682.
8. Sattin, A., Rall, T. W. (1970). The effect of adenosine and adenine nucleotides on the cyclic adenosine 3', 5'-phosphate content of guinea pig cerebral cortex slices. Molecular Pharmacology, 6, 13-23.
9. Fredholm, B. B., Ijzerman, A. P., Jacobson, K. A., Klotz, K.-N., Linden, J. (2001). International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacological Reviews, 53, 527-5522.
10. Fredholm, B. B., Battig, K., Holmen, J., Nehlig, A., Zvartau, E. E. (1999). Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacological Reviews, 51, 83-133.
11. Lukashev, D. E., Smith, P. T., Caldwell, C. C., Ohta, A., Apasov, S. G., Sitkovsky, M. V. (2003). Analysis of A2a receptor-deficient mice reveals no significant compensatory increases in the expression of A2b, A1, and A3 adenosine receptors in lymphoid organs. Biochemical Pharmacology, 65, 2081-2090.
12. Chambers, C. A., Kuhns, M. S., Egen, J. G., & Allison, J. P. (2001). CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annual Review of Immunology, 19, 565-594.
13. Koshiba, M., Kojima, H., Huang, S., Apasov, S., & Sitkovsky, M. V. (1997). Memory of extracellular adenosine/A2a purinergic receptor-mediated signalling in murine T cells. Journal of Biological Chemistry, 272, 25881-25889.
14. Koshiba, M., Rosin, D. L., Hayashi, N., Linden, J., & Sitkovsky, M. V. (1999). Patterns of A2A extracellular adenosine receptor expression in different functional subsets of human peripheral T cells. Flow cytometry studies with anti-A2A receptor monoclonal antibodies. Molecular Pharmacology, 55, 614-624.
15. Huang, S., Koshiba, M., Apasov, S., & Sitkovsky, M. (1997). Role of A2a adenosine receptor-mediated signaling in inhibition of T cell activation and expansion. Blood, 90, 1600-1610.
16. Takayama, H., & Sitkovsky, M. V. (1988). Potential use of antagonists of cAMP-dependent protein kinase to block inhibition and modulate T-cell receptor-triggered activation of cytotoxic T-lymphocytes. Journal of Pharmaceutical Sciences, 78, 8-10.
17. Sugiyama, H., Chen, P., Hunter, M., Taffs, R., & Sitkovsky, M. (1992). The dual role of the cAMP-dependent protein kinase C alpha subunit in T-cell receptor-triggered T-lymphocytes effector functions. Journal of Biological Chemistry, 267, 25256-25263.
18. Torgersen, K. M., Vang, T., Abrahamsen, H., Yaqub, S., & Tasken, K. (2002). Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell Signal, 14, 1-9.
19. Sun, H., Gutierrez, P., Jackson, M. J., Kundu, N., & Fulton, A. M. (2000). Essential role of nitric oxide and interferon-gamma for tumor immunotherapy with interleukin-10. Journal of Immunotherapy, 23, 208-214.
20. Poehlein, C. H., Hu, H. M., Yamada, J., Assmann, I., Alvord, W. G., Urba, W. J., et al. (2003). TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells. Journal of Immunology, 170, 2004-2013.
21. Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., & Old, L. J., et al. (2001). IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature, 410, 1107-1111.
22. Naito, Y., Saito, K., Shiiba, K., Ohuchi, A., Saigenji, K., & Nagura, H., et al. (1998). CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Research, 58, 3491-3494.
23. Schumacher, K., Haensch, W., Roefzaad, C., & Schlag, P. M. (2001). Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Research, 61, 3932-3936.
24. Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., et al. (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. New England Journal of Medicine, 348, 203-213.
25. Nagorsen, D., Scheibenbogen, C., Marincola, F., Letsch, A., & Keilholz, U. (2003). Natural T cell immunity against cancer. Clinical Cancer Research, 9, 4296-4303.
26. Rosenberg, S. A. (2001). Progress in the development of immunotherapy for the treatment of patients with cancer. Journal of Internal Medicine, 250, 462-475.
27. Melief, C. J., Van Der Burg, S. H., Toes, R. E., Ossendorp, F., & Offringa, R. (2002). Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunological Reviews, 188, 177-182.
28. Hurwitz, A. A., Yanover, P., Markowitz, M., Allison, J. P., & Kwon, E. D. (2003). Prostate cancer: Advances in immunotherapy. Bio Drugs, 17, 131-138.
29. Ribas, A., Butterfield, L. H., Glaspy, J. A., & Economou, J. S. (2003). Current developments in cancer vaccines and cellular immunotherapy. Journal of Clinical Oncology, 21, 2415-2432.
30. Wang, X. Y., Kazim, L., Repasky, E. A., & Subjeck, J. R. (2003). Immunization with tumor-derived ER chaperone grp170 elicits tumor-specific CD8+ T-cell responses and reduces pulmonary metastatic disease. International Journal of Cancer, 105, 226-231.
31. Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., & Sherry, R. M., et al. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science, 314, 126-129.
32. Gattinoni, L., Powell, D. J., Jr., Rosenberg, S. A., & Restifo, N. P. (2006). Adoptive immunotherapy for cancer: building on success. Nature Reviews. Immunology, 6, 383-393.
33. Chouhury, A., Mosolits, S., Kokhaei, P., Hansson, L., Palma, M., & Mellstedt, H. (2006). Clinical results of vaccine therapy for cancer: Learning from history for improving the future. Advances in Cancer Research, 95, 147-202.
34. Hodi, F. S. (2006). Dranoff G, combinatorial cancer immunotherapy. Advances in Immunology, 90, 341-368.
35. Elia, L., Aurisicchio, L., Fcciabene, A., Giannetti, P., Ciliberto, G., La Monica, N., et al. (2007). CD4(+)CD25(+) regulatory T-cell-inactivation in combination with adenovirus vaccines enhances T-cell responses and protects mice from tumor challenge. Cancer Gene Therapy, 201-210.
36. Borges, V. F., Kufe, D., & Avigan, D. E. (2002). Update on cancer vaccines. Current Opinion in Gastroenterology, 18, 723-731.
37. Woan, K., & Reddy, V. (2007). Potential therapeutic role of natural killer cells in cancer. Expert Opin Biol Ther, 7, 17-29.
38. van der Vliet, H. J., Balk, S. P., & Exley, M. A. (2006). Natural killer T cell-based cancer immunotherapy. Clinical Cancer Research, 12, 5921-5923.
39. Rabinovich, G. A., Gabrilovich, D., Sotomayor, E. M. (2007). Immunosuppressive strategies that are mediated by tumor cells. Annual Review of Immunology, 25, 267-296.
40. Leen, A. M., Rooney, C. M., & Foster, A. E. (2007). Improving T cell therapy for cancer. Annual Review of Immunology, 25, 243-265.
41. Frumento, G., Piazza, T., Di Carlo, E., & Ferrini, S. (2006). Targeting tumor-related immunosuppression for cancer immunotherapy. Endocr Metab Immune Disord Drug Targets, 6, 233-237.
42. Harlin, H., Kuna, T. V., Peterson, A. C., Meng, Y., & Gajewski, T. F. (2006). Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunology and Immunotherapy, 55, 1185-1197.
43. Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (2000). Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance. Advances in Immunology, 74, 181-273.
44. Hellstrom, I., Hellstrom, K. E., Pierce, G. E., & Yang, J. P. (1968). Cellular and humoral immunity to different types of human neoplasms. Nature, 220, 1352-1354.
45. Hanson, H. L., Donermeyer, D. L., Ikeda, H., White, J. M., Shankaran, V., Old, L. J., et al. (2000). Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity, 13, 265-276.
46. Peng, L., Kjaergaard, J., Plautz, G. E., Awad, M., Drazba, J. A., Shu, S., et al. (2002). Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy. Journal of Immunology, 169, 4811-4821.
47. Kobie, J. J., Wu, R. S., Kurt, R. A., Lou, S., Adelman, M. K., Whitesell, L. J., et al. (2003). Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Research, 63, 1860-1864.
48. Lappas, C. M., Rieger, J. M., & Linden, J. (2005). A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. Journal of Immunology, 174, 1073-1080.
49. Ohta, A., Gorelik, E., Prasad, S. J., Ronchese, F., Lukashev, D., Wong, M. K., et al. (2006). A2A adenosine receptor protects tumors from antitumor T cells. Proceedings of the National Academy of Sciences of the United States of America, 103, 13132-13137.
50. Sitkovsky, M. V. (2003). Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochemical Pharmacology, 65, 493-501.
51. Thiel, M., Chouker, A., Ohta, A., Jackson, E., Caldwell, C., Smith, P., et al. (2005). Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. PLoS Biol, 3, e174.
52. Sitkovsky, M., & Lukashev, D. (2005). Regulation of immune cells by local-tissue oxygen tension: HIF1alpha and adenosine receptors. Nature Reviews Immunology, 5, 712-721.
53. Arnold, F., West, D., & Kumar, S. (1987). Wound healing: The effect of macrophage and tumour derived angiogenesis factors on skin graft vascularization. British Journal of Experimental Pathology, 68, 569-574.
54. Simmen, H. P., Battaglia, H., Giovanoli, P., & Blaser, J. (1994). Analysis of pH, pO2 and pCO2 in drainage fluid allows for rapid detection of infectious complications during the follow-up period after abdominal surgery. Infection, 22, 386-389.
55. Eltzschig, H. K., Thompson, L. F., Karhausen, J., Cotta, R. J., Ibla, J. C., Robson, S. C., et al. (2004). Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: Coordination by extracellular nucleotide metabolism. Blood, 104, 3986-3992.
56. Helmlinger, G., Yuan, F., Dellian, M., & Jain, R. K. (1997). Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation. Nat Med, 3, 177-182.
57. Vaupel, P., Kalinowski, F., & Okunieff, P. (1989). Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Research, 49, 6449-6465.
58. Vaupel, P., Thews, O., & Hoeckel, M. (2001). Treatment resistance of solid tumors: Role of hypoxia and anemia. Medical Oncology, 18, 243-259.
59. Harris, A. L. (2002). Hypoxia-a key regulatory factor in tumour growth. Nature Reviews. Cancer, 2, 38-47.
60. Gorlach, A. (2005). Control of adenosine transport by hypoxia. Circulation Research, 97, 1-3.
61. Arch, J. R., & Newsholme, E. A. (1978). Activities and some properties of 5'-nucleotidase, adenosine kinase and adenosine deaminase in tissues from vertebrates and invertebrates in relation to the control of the concentration and the physiological role of adenosine. Biochemical Journal, 174, 965-977.
62. Lukashev, D., Ohta, A., & Sitkovsky, M. (2004). Targeting hypoxia-A(2A) adenosine receptor-mediated mechanisms of tissue protection. Drug Discovery Today, 9, 403-409.
63. Griffith, D. A., & Jarvis, S. M. (1996). Nucleoside and nucleobase transport systems of mammalian cells. Biochimica and Biophysica Acta, 1286, 153-181.
64. Casanello, P., Torres, A., Sanhueza, F., Gonzalez, M., Farias, M., Gallardo, V., et al. (2005). Equilibrative nucleoside transporter 1 expression is downregulated by hypoxia in human umbilical vein endothelium. Circulation Research, 97, 16-24.
65. Zimmermann, H., & Braun, N. (1999). Ecto-nucleotidases-molecular structures, catalytic properties, and functional roles in the nervous system. Progress in Brain Research, 120, 371-385.
66. Cristalli, G., Costanzi, S., Lambertucci, C., Lupidi, G., Vittori, S., Volpini, R., et al. (2001). Adenosine deaminase: Functional implications and different classes of inhibitors. Medical Research Reviews, 21, 105-128.
67. Decking, U. K., Schlieper, G., Kroll, K., & Schrader, J. (1997). Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release. Circulation Research, 81, 154-164.
68. Kaczmarek, E., Koziak, K., Sevigny, J., Siegel, J. B., Anrather, J., Beaudoin, A. R., et al. (1996). Identification and characterization of CD39/vascular ATP diphosphohydrolase. Journal of Biological Chemistry, 271, 33116-33122.
69. Robson, S. C., Wu, Y., Sun, X., Knosalla, C., Dwyer, K., & Enjyoji, K. (2005). Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Seminars in Thrombosis and Hemostasis, 31, 217-233.
70. Kaczmarek, E., Erb, L., Koziak, K., Jarzyna, R., Wink, M. R., Guckelberger, O., et al. (2005). Modulation of endothelial cell migration by extracellular nucleotides: Involvement of focal adhesion kinase and phosphatidylinositol 3-kinase-mediated pathways. Thrombosis and Haemostasis, 93, 735-742.
71. Dzhandzhugazyan, K. N., Kirkin, A. F., thor Straten, P., & Zeuthen, J. (1998). Ecto-ATP diphosphohydrolase/CD39 is overexpressed in differentiated human melanomas. FEBS Letters, 430, 227-230.
72. Kobayashi, S., Zimmermann, H., & Millhorn, D. E. (2000). Chronic hypoxia enhances adenosine release in rat PC12 cells by altering adenosine metabolism and membrane transport. Journal of Neurochemistry, 74, 621-632.
73. Synnestvedt, K., Furuta, G. T., Comerford, K. M., Louis, N., Karhausen, J., Eltzschig, H. K., et al. (2002). Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. Journal of Clinical Investigation, 110, 993-1002.
74. Caldwell, C. C., Kojima, H., Lukashev, D., Armstrong, J., Farber, M., Apasov, S. G., et al. (2001). Differential effects of physiologically relevant hypoxic conditions on T lymphocyte development and effector functions. Journal of Immunology, 167, 6140-6149.
75. Babior, B. M., Kipnes, R. S., & Curnutte, J. T. (1973). Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. Journal of Clinical Investigation, 52, 741-744.
76. Nathan, C. F., Mercer-Smith, J. A., DeSantis, N. M., & Palladino, M. A. (1982). Role of oxygen in T cell-mediated cytolysis. Journal of Immunology, 129, 2164-2171.
77. McKeehan, W. L. (1982). Glycolysis, glutaminolysis and cell proliferation. Cell Biol Int Rep, 6, 635-650.
78. Levene, P. A., & Meyer, G. M. (1912) The action of leukocytes on glucose. Journal of Biological Chemistry, 11, 361-370.
79. Borregaard, N., & Herlin, T. (1982). Energy metabolism of human neutrophils during phagocytosis. Journal of Clinical Investigation, 70, 550-557.
80. Rathmell, J. C., Vander Heiden, M. G., Harris, M. H., Frauwirth, K. A., & Thompson, C. B. (2000). In the absence of extrinsic signals, nutrient utilization by lymphocytes is insufficient to maintain either cell size or viability. Molecular Cell, 6, 683-692.
81. Semenza, G. L. (1999). Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annual Review of Cell and Developmental Biology, 15, 551-578.
82. Semenza, G. L. (2002). HIF-1 and tumor progression: Pathophysiology and therapeutics. Trends in Molecular Medicine, 8, S62-S67.
83. Semenza, G. L. (2003). Targeting HIF-1 for cancer therapy. Nature Reviews Cancer, 3, 721-732.
84. Semenza, G. L. (2001). HIF-1, O(2), and the 3 PHDs: How animal cells signal hypoxia to the nucleus. Cell, 107, 1-3.
85. Lukashev, D. E., Caldwell, C. C., Ohta, A., Chen, P., & Sitkovsky, M. V. (2001). Differential regulation of two alternatively spliced isoforms of hypoxia-inducible factor-1 alpha in activated T lymphocytes. Journal of Biological Chemistry, 276, 48754-48763.
86. Thornton, R. D., Lane, P., Borghaei, R. C., Pease, E. A., Caro, J., & Mochan, E. (2000). Interleukin 1 induces hypoxia-inducible factor 1 in human gingival and synovial fibroblasts. Biochemical Journal, 350, 307-312.
87. Nakamura, H., Makino, Y., Okamoto, K., Poellinger, L., Ohnuma, K., Morimoto, C., et al. (2005). TCR engagement increases hypoxia-inducible factor-1 alpha protein synthesis via rapamycin-sensitive pathway under hypoxic conditions in human peripheral T cells. Journal of Immunology, 174, 7592-7599.
88. Iyer, N. V., Kotch, L. E., Agani, F., Leung, S. W., Laughner, E., Wenger, R. H., et al. (1998). Cellular and developmental control of O2 homestasis by hypoxia-inducible factor 1a. Genes & Development, 12, 149-162.
89. Cramer, T., Yamzanishi, Y., Clausen, B. E., Forster, I., Pawlinski, R., Mackman, N., et al. (2003). HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell, 112, 645-657.
90. Kojima, H., Gu, H., Nomura, S., Caldwell, C. C., Kobata, T., Carmeliet, P., et al. (2002). Abnormal B lymphocyte development and autoimmunity in hypoxia-inducible factor 1alpha -deficient chimeric mice. Proceedings of the National Academy of Sciences of the United States of America, 99, 2170-2174.
91. Lukashev, D., Klebanov, B., Kojima, H., Grinberg, A., Ohta, A., Berenfeld, L., et al. (2006). Cutting edge: Hypoxia-inducible factor 1alpha and its activation-inducible short isoform I.1 negatively regulate functions of CD4+ and CD8+ T lymphocytes. Journal of Immunology, 177, 4962-4965.
92. Neumann, A. K., Yang, J., Biju, M. P., Joseph, S. K., Johnson, R. S., Haase, V. H., et al. (2005). Hypoxia inducible factor 1 alpha regulates T cell receptor signal transduction. Proceedings of the National Academy of Sciences of the United States of America, 102, 17071-17076.